Undecimal Bio raises $18 million to expand siRNA platform beyond liver diseases
Undecimal Bio, founded by Yaniv Erlich and Shaul Ilan, announced a new financing round that brings in $18 million. The capital will support the company’s effort to develop siRNA therapeutics for targets outside of the liver.
The funding follows a recent spin‑out from Eleven Therapeutics, which separated its business into two distinct entities earlier this summer. Undecimal Bio will focus on broadening the application of RNA‑interference technology.
With this investment, Undecimal Bio joins other siRNA innovators such as Arrowhead and Alnylam, positioning itself to pursue a wider range of disease indications.
The announcement was reported by Anna Brown of News Reporter on October 12, 2026.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Undecimal Bio launches with $18M to take siRNA beyond liver disease”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that